{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:21:27Z","timestamp":1784769687008,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical Research Plan of Shanghai Hospital Development Center","award":["SHDC2020CR4004"],"award-info":[{"award-number":["SHDC2020CR4004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anemia is one of the main complications of chronic kidney disease especially kidney failure, which includes treatment with erythropoiesis-stimulating agents and iron supplementation, including intravenous and oral iron. However, intravenous iron may pose limitations, such as potential infusion reactions. Oral iron is mainly composed of divalent iron, which can excessively stimulate the gastrointestinal tract. Iron polysaccharide complex capsules are a novel oral iron trivalent supplement with higher iron content and lower gastrointestinal irritation. However, since high-quality evidence-based medicinal support is lacking, it is necessary to conduct clinical studies to further evaluate the effectiveness and safety of oral iron polysaccharide complex in chronic kidney disease patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This randomized controlled trial uses an open-label, parallel group design, where the efficacy and safety of maintenance hemodialysis (MHD) participants is evaluated. The experimental group is assigned erythropoietins and iron polysaccharide complex (two capsules each time, bid), and the control group is assigned erythropoietin and sucrose iron (100mg, 2w) injection. Participants (aged 18\u201375 years) undergoing maintenance hemodialysis were considered for screening. Inclusion criteria included hemoglobin (Hb) \u2265110g\/L and &lt; 130g\/L, transferrin saturation (TSAT) &gt; 20% and &lt; 50%, and serum ferritin (SF) &gt; 200\u03bcg\/L and &lt; 500\u03bcg\/L. Exclusion criteria included acute or chronic bleeding, serum albumin &lt; 35g\/L, hypersensitive C-reactive protein (HsCRP) &gt; 10 mg\/L, and severe secondary hyperparathyroidism (iPTH \u2265 800 pg\/mL). Full inclusion and exclusion criteria are described in the \u201cMethods\u201d section. The primary endpoint is TSAT of the participants at week 12. Secondary endpoints include Hb, SF, hematocrit (Hct), HsCRP, pharmacoeconomic evaluation, drug costs, quality of life, and indicators of oxidative stress. The treatment will last for 24 weeks with a follow-up visit at baseline (within 7 days prior to initial treatment) and weeks 4, 8, 12, 16, 20, and 24 after initial treatment. This clinical research includes 9 hemodialysis centers in mainland China and plans to enroll 186 participants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>It is expected that it will provide strong evidence to reveal the clinical efficacy and safety of oral iron in the treatment of chronic CKD-related anemia in MHD patients through this clinical trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/index.aspx\">ChiCTR2000031166<\/jats:ext-link>. Registered on March 23, 2020<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05663-1","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T22:43:32Z","timestamp":1633905812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of polysaccharide iron complex capsules compared with iron sucrose in hemodialysis patients: study protocol for a randomized, open-label, positive control, multicenter trial (IHOPE)"],"prefix":"10.1186","volume":"22","author":[{"given":"Renhua","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"issue":"1","key":"5663_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000442741","volume":"42","author":"L Zuo","year":"2016","unstructured":"Zuo L, Wang M, Hou F, et al. Anemia management in the China dialysis outcomes and practice patterns study.[J]. Blood Purif. 2016;42(1):33.","journal-title":"Blood Purif"},{"issue":"10204","key":"5663_CR2","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2019;394(10204):1145\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(19)30427-1.","journal-title":"The Lancet."},{"issue":"24","key":"5663_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003872","volume":"95","author":"Y Li","year":"2016","unstructured":"Li Y, Shi H, Wang W-M, Peng A, Jiang G-R, Zhang J-Y, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore). 2016;95(24):e3872. https:\/\/doi.org\/10.1097\/MD.0000000000003872.","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"5663_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","volume":"31","author":"EK Batchelor","year":"2020","unstructured":"Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. 2020;31(3):456\u201368. https:\/\/doi.org\/10.1681\/ASN.2019020213.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"5663_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2015.11.005","volume":"9","author":"AA Hagag","year":"2016","unstructured":"Hagag AA, El-Farargy MS, Elrefaey S, Abo El-enei AM. Study of gonadal hormones in Egyptian female children with sickle cell anemia in correlation with iron overload: single center study. Hematol Oncol Stem Cell Ther. 2016;9(1):1\u20137. https:\/\/doi.org\/10.1016\/j.hemonc.2015.11.005.","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"5663_CR6","doi-asserted-by":"crossref","unstructured":"Nhan Hieu Dinh, Suzanne Monivong Cheanh Beaupha, Loan Thi Anh Tran. The validity of reticulocyte hemoglobin content and percentage of hypochromic red blood cells for screening iron deficiency anemia among patients with end-stage renal disease: a retrospective analysis. BMC Nephrol. 2020;21(1):142. doi: 10.1186\/s12882-020-01796-8.","DOI":"10.1186\/s12882-020-01796-8"},{"issue":"20","key":"5663_CR7","first-page":"1463","volume":"101","author":"Renal Anemia Guidelines Working Group of Chinese Medical Doctor Association","year":"2021","unstructured":"Renal Anemia Guidelines Working Group of Chinese Medical Doctor Association. Clinical practice guide for diagnosis and treatment of renal anemia in China. Chin Med J. 2021;101(20):1463\u2013502.","journal-title":"Chin Med J."},{"issue":"3","key":"5663_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1525-139X.2011.00938.x","volume":"24","author":"H Yamamoto","year":"2011","unstructured":"Yamamoto H, Tsubakihara Y. Limiting iron supplementation for anemia in dialysis patients\u2014the basis for Japan\u2019s conservative guidelines. Semin Dial. 2011;24(3):269\u201371. https:\/\/doi.org\/10.1111\/j.1525-139X.2011.00938.x.","journal-title":"Semin Dial."},{"issue":"7","key":"5663_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-016-0569-0","volume":"76","author":"G Rostoker","year":"2016","unstructured":"Rostoker G. Nosratola D Vaziri, Steven Fishbane. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs. 2016;76(7):741\u201357. https:\/\/doi.org\/10.1007\/s40265-016-0569-0.","journal-title":"Drugs."},{"issue":"5","key":"5663_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447\u201358.","journal-title":"N Engl J Med"},{"issue":"jan08 15","key":"5663_CR11","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ."},{"issue":"1","key":"5663_CR12","doi-asserted-by":"publisher","first-page":"e000171","DOI":"10.1136\/bmjsem-2016-000171","volume":"2","author":"CM Friedenreich","year":"2016","unstructured":"Friedenreich CM, Pialoux V, Wang Q, Shaw E, Brenner DR, Waltz X, et al. Effects of exercise on markers of oxidative stress: an ancillary analysis of the Alberta Physical Activity and Breast Cancer Prevention Trial. BMJ Open Sport Exerc Med. 2016;2(1):e000171. https:\/\/doi.org\/10.1136\/bmjsem-2016-000171.","journal-title":"BMJ Open Sport Exerc Med"},{"issue":"1","key":"5663_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u20132.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"5663_CR14","unstructured":"Eq-5d Questionnary. 2012. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed Apr 2017."},{"key":"5663_CR15","unstructured":"Good Clinical Practice (GCP) Instructions of National Medical Products Administration of PR. China. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20200426162401243.html. Annex to Announcement No.57 of the National Medical Products Administration and National Health Commission in 2020. Accessed Apr 2020."},{"key":"5663_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17474086.2017.1343140","volume":"10","author":"S Barni","year":"2017","unstructured":"Barni S, Petrelli PGF, Garc\u00eda-Erce JA, Pedrazzoli P, Rosti G, Giordano G, et al. Position paper on management of iron deficiency in adult cancer patients. Expert Rev Hematol. 2017;10:685\u201395.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"5663_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/THC-151074","volume":"24","author":"X Calvet","year":"2016","unstructured":"Calvet X, Gen\u00e9 E, \u00c0ngelRu\u00edz M, Figuerola A, Villoria A, Cucala M, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technol Health Care. 2016;24(1):111\u201320. https:\/\/doi.org\/10.3233\/THC-151074.","journal-title":"Technol Health Care."},{"key":"5663_CR18","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1111\/hdi.12553","volume":"21","author":"GAM Kortman","year":"2017","unstructured":"Kortman GAM, Reijnders D, Swinkels DW. Oral iron supplementation: potential implications for the gut microbiome and metabolome in patients with CKD. Hemodial Int. 2017;21:S28\u201336. https:\/\/doi.org\/10.1111\/hdi.12553.","journal-title":"Hemodial Int."},{"key":"5663_CR19","first-page":"1673","volume":"36","author":"JY Du","year":"2019","unstructured":"Du JY, Chai QQ, Zhang C, et al. Efficacy and safety of polysaccharide iron complex in the treatment of renal anemia: a meta-analysis (Chinese version). Chin J Mod Appl Pharm. 2019;36:1673\u20137.","journal-title":"Chin J Mod Appl Pharm."},{"key":"5663_CR20","first-page":"492","volume":"16","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wu XY. Clinical observation of Shengxuening tablets in the treatment of renal anemia in maintenance peritoneal dialysis (Chinese version). J Clin Nephrol. 2016;16:492\u20135.","journal-title":"J Clin Nephrol."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05663-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05663-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05663-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T22:45:46Z","timestamp":1633905946000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05663-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,10]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5663"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05663-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,10]]},"assertion":[{"value":"2 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has been approved by the ethics committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (approval number: 2019-048). Informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"I will be willing to provide a model consent form on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"691"}}